The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB Mice
Open accessAbstract
Indirect evidence suggests that type-I interferons (IFN-α/β) play a significant role in the pathogenesis of lupus. To directly examine the contribution of these pleiotropic molecules, we created congenic NZB mice lacking the α-chain of IFN-α/βR, the common receptor for the multiple IFN-α/β species. Compared with littermate controls, homozygous IFN-α/βR-deleted NZB mice had significantly reduced anti-erythrocyte autoantibodies, erythroblastosis, hemolytic anemia, anti-DNA autoantibodies, kidney disease, and mortality. These reductions were intermediate in the heterozygous-deleted mice. The disease-ameliorating effects were accompanied by reductions in splenomegaly and in several immune cell subsets, including B-1 cells, the major producers of anti-erythrocyte autoantibodies. Decreases of B and T cell proliferation in vitro and in vivo, and of dendritic cell maturation and T cell stimulatory activity in vitro were also detected. Absence of signaling through the IFN-α/βR, however, did not affect increased basal levels of the IFN-responsive p202 phosphoprotein, encoded by a polymorphic variant of the Ifi202 gene associated with the Nba2 predisposing locus in NZB mice. The data indicate that type-I IFNs are important mediators in the pathogenesis of murine lupus, and that reducing their activity in the human counterpart may be beneficial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
IRF Family of Transcription Factors as Regulators of Host Defense
Taniguchi, T., Ogasawara, K., Takaoka, A., & Tanaka, N. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.623 · Cited by 1,658
Natural adjuvants: Endogenous activators of dendritic cells
Gallucci, S., Lolkema, M., & Matzinger, P. (1999) · Nature Medicine · doi:10.1038/15200 · Cited by 1,602
Andrews, B. S., Eisenberg, R. A., Theofilopoulos, A. N., Izui, S., Wilson, C. B., McConahey, P. J., Murphy, E. D., Roths, J. B., & Dixon, F. J. (1978) · The Journal of experimental medicine · doi:10.1084/jem.148.5.1198 · Cited by 1,598
Self-citationMurine Models of Systemic Lupus Erythematosus
Theofilopoulos, A. N., & Dixon, F. J. (1985) · Advances in Immunology · doi:10.1016/s0065-2776(08)60342-9 · Cited by 1,550
Self-citationInduction of Dendritic Cell Differentiation by IFN-α in Systemic Lupus Erythematosus
Blanco, P., Palucka, A. K., Gill, M., Pascual, V., & Banchereau, J. (2001) · Science · doi:10.1126/science.1064890 · Cited by 1,266
Potent and Selective Stimulation of Memory-Phenotype CD8+ T Cells In Vivo by IL-15
Zhang, X., Sun, S., Hwang, I., Tough, D. F., & Sprent, J. (1998) · Immunity · doi:10.1016/s1074-7613(00)80564-6 · Cited by 1,245
Induction of Bystander T Cell Proliferation by Viruses and Type I Interferon in Vivo
Tough, D. F., Borrow, P., & Sprent, J. (1996) · Science · doi:10.1126/science.272.5270.1947 · Cited by 1,077
Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology
Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-Dambuyant, C., Vicari, A., O'Garra, A., Biron, C., Brière, F., et al. (2001) · Nature Immunology · doi:10.1038/ni736 · Cited by 1,022
Le Bon, A., Schiavoni, G., D'Agostino, G., Gresser, I., Belardelli, F., & Tough, D. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00126-1 · Cited by 974
Type I Interferons Keep Activated T Cells Alive
Marrack, P., Kappler, J., & Mitchell, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.3.521 · Cited by 759
CYCLINS AND CELL CYCLE CHECKPOINTS
Johnson, D. G., & Walker, C. L. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.295 · Cited by 719
Ernst, B., Lee, D.-S., Chang, J. M., Sprent, J., & Surh, C. D. (1999) · Immunity · doi:10.1016/s1074-7613(00)80092-8 · Cited by 717
Nakano, H., Yanagita, M., & Gunn, M. D. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1171 · Cited by 713
Interferons α and β as Immune Regulators—A New Look
Biron, C. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00154-6 · Cited by 667
Matsuyama, T., Kimura, T., Kitagawa, M., Pfeffer, K., Kawakami, T., Watanabe, N., Kündig, T. M., Amakawa, R., Kishihara, K., Wakeham, A., et al. (1993) · Cell · doi:10.1016/s0092-8674(05)80086-8 · Cited by 649
Maintaining the norm: T-cell homeostasis
Jameson, S. C. (2002) · Nature Reviews Immunology · doi:10.1038/nri853 · Cited by 599
A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells
Sedgwick, J. D., & Holt, P. G. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90091-1 · Cited by 560
Delineating the Genetic Basis of Systemic Lupus Erythematosus
Wakeland, E. K., Liu, K., Graham, R. R., & Behrens, T. W. (2001) · Immunity · doi:10.1016/s1074-7613(01)00201-1 · Cited by 556
A weak signal for strong responses: interferon-alpha/beta revisited
Taniguchi, T., & Takaoka, A. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35073080 · Cited by 483
Systemic Lupus Erythematosus: Presence in Human Serum of an Unusual Acid-Labile Leukocyte Interferon
Preble, O. T., Black, R. J., Friedman, R. M., Klippel, J. H., & Vilček, J. (1982) · Science · doi:10.1126/science.6176024 · Cited by 459
CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity.
Ansel, K. M., Harris, R. B. S., & Cyster, J. G. (2002) · Immunity · doi:10.1016/s1074-7613(01)00257-6 · Cited by 449
Chu, C.-Q., Wittmer, S., & Dalton, D. K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.1.123 · Cited by 418
Evidence for an Interferon-Inducible Gene, Ifi202, in the Susceptibility to Systemic Lupus
Rozzo, S. J., Allard, J. D., Choubey, D., Vyse, T. J., Izui, S., Peltz, G., & Kotzin, B. L. (2001) · Immunity · doi:10.1016/s1074-7613(01)00196-0 · Cited by 356
Self-citationInterferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice.
Balomenos, D., Rumold, R., & Theofilopoulos, A. N. (1998) · Journal of Clinical Investigation · doi:10.1172/jci750 · Cited by 356
Self-citationCross Talk Between Interferon-γ and -α/β Signaling Components in Caveolar Membrane Domains
Takaoka, A., Mitani, Y., Suemori, H., Sato, M., Yokochi, T., Noguchi, S., Tanaka, N., & Taniguchi, T. (2000) · Science · doi:10.1126/science.288.5475.2357 · Cited by 319
GENETIC SUSCEPTIBILITY TO SYSTEMIC LUPUS ERYTHEMATOSUS
Vyse, T. J., & Kotzin, B. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.261 · Cited by 313
Roles of interferon-gamma and interleukin-4 in murine lupus.
Peng, S. L., Moslehi, J., & Craft, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119361 · Cited by 298
Jahng, A. W., Maricic, I., Pedersen, B., Burdin, N., Naidenko, O., Kronenberg, M., Koezuka, Y., & Kumar, V. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1789 · Cited by 291
Induction of Type I Diabetes by Interferon-α in Transgenic Mice
Stewart, T. A., Hultgren, B., Huang, X., Pitts-Meek, S., Hully, J., & MacLachlan, N. J. (1993) · Science · doi:10.1126/science.8100367 · Cited by 285
Self-citationMurakami, M., Tsubata, T., Okamoto, M., Shimizu, A., Kumagai, S., Imura, H., & Honjo, T. (1992) · Nature · doi:10.1038/357077a0 · Cited by 278
IFN‐α/β enhances BCR‐dependent B cell responses
Braun, D., Caramalho, I., & Demengeot, J. (2002) · International Immunology · doi:10.1093/intimm/14.4.411 · Cited by 268
Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy
Ioannou, Y., & Isenberg, D. A. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200007)43:7<1431::aid-anr3>3.0.co;2-e · Cited by 252
Hida, S., Ogasawara, K., Sato, K., Abe, M., Takayanagi, H., Yokochi, T., Sato, T., Hirose, S., Shirai, T., Taki, S., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00064-9 · Cited by 251
Schwarting, A., Wada, T., Kinoshita, K., Tesch, G. H., & Kelley, V. R. (1998) · PubMed · Cited by 244
Burlingame, R. W., Rubin, R. L., Balderas, R. S., & Theofilopoulos, A. N. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116378 · Cited by 230
Self-citationTheofilopoulos, A. N., Koundouris, S., Kono, D. H., & Lawson, B. R. (2001) · Arthritis Research · doi:10.1186/ar290 · Cited by 215
Self-citationSchwarting, A., Wada, T., Kinoshita, K., Tesch, G., & Rubin Kelley, V. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.1.494 · Cited by 210
Haas, C., Ryffel, B., & Hir, M. L. (1998) · PubMed · Cited by 209
An etiopathogenic role for the type I IFN system in SLE
Rönnblom, L., & Alm, G. V. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01955-x · Cited by 197
Ozmen, L., Roman, D., Fountoulakis, M., Schmid, G., Ryffel, B., & Garotta, G. (1995) · European Journal of Immunology · doi:10.1002/eji.1830250103 · Cited by 184
Balasa, B., Deng, C., Lee, J., Bradley, L. M., Dalton, D. K., Christadoss, P., & Sarvetnick, N. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.3.385 · Cited by 183
Haas, C., Ryffel, B., & Le Hir, M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.8.3713 · Cited by 180
Impairment of T and B Cell Development by Treatment with a Type I Interferon
Lin, Q., Dong, C., & Cooper, M. D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.1.79 · Cited by 163
IFNα/β promotes cell survival by activating NF-κB
Yang, C. H., Murti, A., Pfeffer, S. R., Basu, L., Kim, J. G., & Pfeffer, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250477397 · Cited by 162
Treatment of murine lupus with cDNA encoding IFN-γR/Fc
Lawson, B. R., Prud’homme, G. J., Chang, Y., Gardner, H. A., Kuan, J., Kono, D. H., & Theofilopoulos, A. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10167 · Cited by 158
Self-citationPrevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells
Murakami, M., Yoshioka, H., Shirai, T., Tsubata, T., & Honjo, T. (1995) · International Immunology · doi:10.1093/intimm/7.5.877 · Cited by 155
Tada, Y., Ho, A., Matsuyama, T., & Mak, T. W. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.2.231 · Cited by 133
The pathogenesis of autoimmunity in New Zealand
Borchers, A. T., Ansari, A. A., Hsu, T. C., Kono, D. H., & Gershwin, M. E. (2000) · Seminars in Arthritis and Rheumatism · doi:10.1053/sarh.2000.7173 · Cited by 132
Self-citationPenninger, J. M., Sirard, C., Mittrücker, H., Chidgey, A. P., Kozieradzki, I., Nghiem, M. P., Hakem, A., Kimura, T., Timms, E. M., Boyd, R. L., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80527-0 · Cited by 118
Zhang, G.-X., Xiao, B. G., Bai, X., et al. (1999) · PubMed · Cited by 109
Agenès, F., & Freitas, A. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.319 · Cited by 102
Genetics of Systemic Autoimmunity in Mouse Models of Lupus
Kono, D. H., & Theofilopouuos, A. N. (2000) · International Reviews of Immunology · doi:10.3109/08830180009055504 · Cited by 92
Self-citationByrnes, A. A., McArthur, J. C., & Karp, C. L. (2001) · Annals of Neurology · doi:10.1002/ana.10084 · Cited by 82
Nisitani, S., Tsubata, T., Murakami, M., & Honjo, T. (1995) · European Journal of Immunology · doi:10.1002/eji.1830251110 · Cited by 81
Inhibition of B Cell Receptor-Mediated Apoptosis by IFN
Su, L., & David, M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.11.6317 · Cited by 70
Immunotherapy of multiple sclerosis: Where are we? Where should we go?
Martinꝉ, R., Stürzebecher, C.-S., & McFarland, H. F. (2001) · Nature Immunology · doi:10.1038/ni0901-785 · Cited by 66
Requirement of the IFN‐α/β‐induced CXCR3 chemokine signalling for CD8+ T cell activation
Ogasawara, K., Hida, S., Weng, Y., Saiura, A., Sato, K., Takayanagi, H., Sakaguchi, S., Yokochi, T., Kodama, T., Naitoh, M., et al. (2002) · Genes to Cells · doi:10.1046/j.1365-2443.2002.00515.x · Cited by 66
Complete Suppression of Insulitis and Diabetes in NOD mice Lacking Interferon Regulatory Factor-1
NAKAZAWA, T., Satoh, J., Takahashi, K., Sakata, Y., Ikehata, F., Takizawa, Y., Bando, S.-I., Housai, T., Li, Y., Chen, C., et al. (2001) · Journal of Autoimmunity · doi:10.1006/jaut.2001.0531 · Cited by 60
Interferon-inducible p202 in the susceptibility to systemic lupus
Choubey, D. (2002) · Frontiers in bioscience · doi:10.2741/a921 · Cited by 58
Self-citationCarpenter, D. F., Steinberg, A. D., Schur, P. H., & Talal, N. (1970) · PubMed · Cited by 57
Balabanian, K., Foussat, A., Bouchet‐Delbos, L., et al. (2002) · Blood · doi:10.1182/blood.v99.2.427 · Cited by 54
Sabzevari, H., Propp, S. S., Kono, D. H., & Theofilopoulos, A. N. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270813 · Cited by 43
Self-citationWatanabe, N., Ikuta, K., Nisitani, S., Chiba, T., & Honjo, T. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011519 · Cited by 42
Yang, C. H., Murti, A., Pfeffer, S. R., et al. (2000) · Cited by 34
Velupillai, P., Sypek, J. P., & Harn, D. A. (1996) · Infection and Immunity · doi:10.1128/iai.64.11.4557-4560.1996 · Cited by 23
Chen, S., Takeoka, Y., Pike-Nobile, L., et al. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4398 · Cited by 17
In Vitro and In Vivo Expression Analysis of the Interferon-Inducible 203 Gene
Gribaudo, G., Riera, L., Hertel, L., & Landolfo, S. (1999) · Journal of Interferon & Cytokine Research · doi:10.1089/107999099314270 · Cited by 17
Cited by
Fox, R. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66990-5 · Cited by 1,828
TYPE I INTERFERONS (α/β) IN IMMUNITY AND AUTOIMMUNITY
Theofilopoulos, A. N., Baccala, R., Beutler, B., & Kono, D. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115843 · Cited by 1,185
Self-citationChristensen, S. R., Shupe, J., Nickerson, K., Kashgarian, M., Flavell, R. A., & Shlomchik, M. J. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.013 · Cited by 1,090
Jego, G., Palucka, A. K., Blanck, J.-P., Chalouni, C., Pascual, V., & Banchereau, J. (2003) · Immunity · doi:10.1016/s1074-7613(03)00208-5 · Cited by 1,067
Type I Interferon in Systemic Lupus Erythematosus and Other Autoimmune Diseases
Banchereau, J., & Pascual, V. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.010 · Cited by 963
Metadata
- Authors
- Santiago-Raber, M.-L., Baccala, R., Haraldsson, K. M., Choubey, D., Stewart, T. A., Kono, D. H., & Theofilopoulos, A. N.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2003-03-17
- Volume
- 197
- Issue
- 6
- Pages
- 777-788
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2016899230
- Cited by
- 509
- References
- 68
- FWCI
- 21.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.